Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma
AUTOR(ES)
Lisle, Jennifer W.
FONTE
Springer-Verlag
RESUMO
Synovial sarcoma generally is associated with poor prognosis. With recent advances in molecular biology, it has become apparent not all synovial sarcomas share the same tumor biology. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. We therefore assessed the clinical value of 18F-FDG-PET-derived maximum standard uptake value (SUVmax) for predicting survival in patients with synovial sarcoma. 18F-FDG-PET was performed in 44 patients with synovial sarcoma before therapy and resection. SUVmax was calculated for each tumor and then evaluated for prognostic usefulness along with metastasis at presentation, tumor grade, histopathologic subtype, age, gender, postsurgical margins, anatomic location, and tumor size for overall survival and progression-free survival. SUVmax ranged from 1.2 to 13.0 (median, 4.35). Pretherapy tumor SUVmax predicted overall survival and progression-free survival. Patients presenting with a SUVmax greater than 4.35 had a decreased disease-free survival and were therefore at high risk for having local recurrences and metastatic disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2674162Documentos Relacionados
- FDG‐PET in meningeal lymphomatosis
- Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
- More on the Timing and Meaning of FDG-PET Abnormalities in Partial Epilepsy
- Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma
- Hipometabolismo cerebral em pacientes com esclerose mesial temporal demonstrado pelo FDG-PET
